Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Gas Research
Published in: Medical Gas Research 1/2015

Open Access 01-12-2015 | Research

Exogenous hydrogen sulfide mitigates the fatty liver in obese mice through improving lipid metabolism and antioxidant potential

Authors: Dongdong Wu, Nairui Zheng, Kunqing Qi, Huijun Cheng, Ziqiang Sun, Biao Gao, Youjing Zhang, Wuyan Pang, Chaoshen Huangfu, Shaoping Ji, Mengzhou Xue, Ailing Ji, Yanzhang Li

Published in: Medical Gas Research | Issue 1/2015

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. Hydrogen sulfide (H2S) plays an important role in physiology and pathophysiology of liver. However, whether exogenous H2S could mitigate the hepatic steatosis in mice remains unclear. The aim of this study is to evaluate the effects of H2S on fatty liver.

Methods

C57BL/6 mice were fed with either a high-fat diet (HFD) or a normal fat diet (NFD) for 16 weeks. After 12 weeks of feeding, the HFD-fed mice were injected one time per day with NaHS or saline for the followed 4 weeks.

Results

Compared to NFD, HFD could induce an accumulation of lipids in liver and a damage of hepatic structure. Compared to saline treatment, in the liver of HFD fed mice H2S treatment could significantly (1) recover the structure; (2) decrease the accumulation of lipids including triglyceride (TG) and total cholesterol (TC); (3) decrease the expression of fatty acid synthase (FAS) and increase the expression of carnitine palmitoyltransferase-1 (CPT-1); (4) reduce malondialdehyde (MDA) levels; (5) increase the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx).

Conclusion

H2S could mitigate the fatty liver by improving lipid metabolism and antioxidant potential in HFD-induced obese mice.
Literature
1.
2.
Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713–23.PubMedCrossRef
3.
4.
Mani S, Cao W, Wu L, Wang R. Hydrogen sulfide and the liver. Nitric Oxide. 2014;41C:62–71.CrossRef
5.
Xue R, Hao DD, Sun JP, Li WW, Zhao MM, Li XH, et al. Hydrogen sulfide treatment promotes glucose uptake by increasing insulin receptor sensitivity and ameliorates kidney lesions in type 2 diabetes. Antioxid Redox Signal. 2013;19:5–23.PubMedCentralPubMedCrossRef
6.
Yang G, Tang G, Zhang L, Wu L, Wang R. The pathogenic role of cystathionine gamma-lyase/hydrogen sulfide in streptozotocin-induced diabetes in mice. Am J Pathol. 2011;179:869–79.PubMedCentralPubMedCrossRef
7.
Tan G, Pan S, Li J, Dong X, Kang K, Zhao M, et al. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PLoS One. 2011;6:e25943.PubMedCentralPubMedCrossRef
8.
Jain SK, Manna P, Micinski D, Lieblong BJ, Kahlon G, Morehead L, et al. In African American type 2 diabetic patients, is vitamin D deficiency associated with lower blood levels of hydrogen sulfide and cyclic adenosine monophosphate, and elevated oxidative stress? Antioxid Redox Signal. 2013;18:1154–8.PubMedCentralPubMedCrossRef
9.
Luo ZL, Tang LJ, Wang T, Dai RW, Ren JD, Cheng L, et al. Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol. 2014;29:215–22.PubMedCrossRef
10.
Kang K, Zhao M, Jiang H, Tan G, Pan S, Sun X. Role of hydrogen sulfide in hepatic ischemia-reperfusion-induced injury in rats. Liver Transpl. 2009;15:1306–14.PubMedCrossRef
11.
Morsy MA, Ibrahim SA, Abdelwahab SA, Zedan MZ, Elbitar HI. Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice. Life Sci. 2010;87:692–8.PubMedCrossRef
12.
Helmy N, Prip-Buus C, Vons C, Lenoir V, Abou-Hamdan A, Guedouari-Bounihi H, et al. Oxidation of hydrogen sulfide by human liver mitochondria. Nitric Oxide. 2014;41:105–12.PubMedCrossRef
13.
Wang CN, Liu YJ, Duan GL, Zhao W, Li XH, Zhu XY, et al. CBS and CSE Are Critical for Maintenance of Mitochondrial Function and Glucocorticoid Production in Adrenal Cortex. Antioxid Redox Signal. 2014;21:2192–207.PubMedCrossRef
14.
Bos EM, Wang R, Snijder PM, Boersema M, Damman J, Fu M, et al. Cystathionine gamma-lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol. 2013;24:759–70.PubMedCentralPubMedCrossRef
15.
Du JT, Li W, Yang JY, Tang CS, Li Q, Jin HF. Hydrogen sulfide is endogenously generated in rat skeletal muscle and exerts a protective effect against oxidative stress. Chin Med J (Engl). 2013;126:930–6.
16.
Yao LL, Huang XW, Wang YG, Cao YX, Zhang CC, Zhu YC. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol. 2010;298:H1310–9.PubMedCrossRef
17.
Lo Faro ML, Fox B, Whatmore JL, Winyard PG, Whiteman M. Hydrogen sulfide and nitric oxide interactions in inflammation. Nitric Oxide. 2014;41:38–47.PubMedCrossRef
18.
Szabo C, Coletta C, Chao C, Modis K, Szczesny B, Papapetropoulos A, et al. Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci U S A. 2013;110:12474–9.PubMedCentralPubMedCrossRef
19.
Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos P, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U S A. 2012;109:9161–6.PubMedCentralPubMedCrossRef
20.
Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal. 2010;12:1065–77.PubMedCrossRef
21.
Polhemus DJ, DJ L. Emergence of Hydrogen Sulfide as an Endogenous Gaseous Signaling Molecule in Cardiovascular Disease. Circ Res. 2014;114:730–7.PubMedCrossRef
22.
Ge SN, Zhao MM, Wu DD, Chen Y, Wang Y, Zhu JH, et al. Hydrogen Sulfide Targets EGFR Cys797/Cys798 Residues to Induce Na/K-ATPase Endocytosis and Inhibition in Renal Tubular Epithelial Cells and Increase Sodium Excretion in Chronic Salt-Loaded Rats. Antioxid Redox Signal. 2014;21:2061–82.PubMedCentralPubMedCrossRef
23.
Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587–90.PubMedCentralPubMedCrossRef
24.
Shirozu K, Tokuda K, Marutani E, Lefer D, Wang R, Ichinose F. Cystathionine gamma-lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure. Antioxid Redox Signal. 2014;20:204–16.PubMedCentralPubMedCrossRef
25.
Peh MT, Anwar AB, Ng DS, Atan MS, Kumar SD, Moore PK. Effect of feeding a high fat diet on hydrogen sulfide (HS) metabolism in the mouse. Nitric Oxide. 2014;41:138–45.PubMedCrossRef
26.
Hwang SY, Sarna LK, Siow YL, Karmin O. High-fat diet stimulates hepatic cystathionine beta-synthase and cystathionine gamma-lyase expression. Can J Physiol Pharmacol. 2013;91:913–9.PubMedCrossRef
27.
Gao M, Bu L, Ma Y, Liu D. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. PLoS One. 2013;8:e65641.PubMedCentralPubMedCrossRef
28.
Park MY, Jang HH, Kim JB, Yoon HN, Lee JY, Lee YM, et al. Hog millet (Panicum miliaceum L.)-supplemented diet ameliorates hyperlipidemia and hepatic lipid accumulation in C57BL/6 J-ob/ob mice. Nutr Res Pract. 2011;5:511–9.PubMedCentralPubMedCrossRef
29.
Ko C, O’Rourke SM, Huang LS. A fish oil diet produces different degrees of suppression of apoB and triglyceride secretion in human apoB transgenic mouse strains. J Lipid Res. 2003;44:1946–55.PubMedCrossRef
30.
Li Y, Tong X, Rumala C, Clemons K, Wang S. Thrombospondin1 deficiency reduces obesity-associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One. 2011;6:e26656.PubMedCentralPubMedCrossRef
31.
Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.PubMedCentralPubMedCrossRef
32.
Wang T, Yang P, Zhan Y, Xia L, Hua Z, Zhang J. Deletion of circadian gene Per1 alleviates acute ethanol-induced hepatotoxicity in mice. Toxicology. 2013;314:193–201.PubMedCrossRef
33.
Song M, Schuschke DA, Zhou Z, Chen T, Pierce Jr WM, Wang R, et al. High fructose feeding induces copper deficiency in Sprague–Dawley rats: a novel mechanism for obesity related fatty liver. J Hepatol. 2012;56:433–40.PubMedCentralPubMedCrossRef
34.
Jwa H, Choi Y, Park UH, Um SJ, Yoon SK, Park T. Piperine, an LXRalpha antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. Biochem Pharmacol. 2012;84:1501–10.PubMedCrossRef
35.
DeAngelis RA, Markiewski MM, Taub R, Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology. 2005;42:1148–57.PubMedCrossRef
36.
37.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51.PubMedCentralPubMedCrossRef
38.
Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol. 2010;21:329–36.PubMedCrossRef
39.
Peinado JR, Quiros PM, Pulido MR, Marino G, Martinez-Chantar ML, Vazquez-Martinez R, et al. Proteomic profiling of adipose tissue from Zmpste24−/− mice, a model of lipodystrophy and premature aging, reveals major changes in mitochondrial function and vimentin processing. Mol Cell Proteomics. 2011;10(M111):008094.PubMed
40.
Brown NF, Hill JK, Esser V, Kirkland JL, Corkey BE, Foster DW, et al. Mouse white adipocytes and 3 T3-L1 cells display an anomalous pattern of carnitine palmitoyltransferase (CPT) I isoform expression during differentiation. Inter-tissue and inter-species expression of CPT I and CPT II enzymes. Biochem J. 1997;327(Pt 1):225–31.PubMedCentralPubMed
41.
McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;244:1–14.PubMedCrossRef
42.
Gill SS, Tuteja N. Reactive oxygen species and antioxidant machinery in abiotic stress tolerance in crop plants. Plant Physiol Biochem. 2010;48:909–30.PubMedCrossRef
43.
Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 2013;58:395–8.PubMedCrossRef
44.
Li Y, Li M, Shi J, Yang X, Wang Z. Hepatic antioxidative responses to PCDPSs and estimated short-term biotoxicity in freshwater fish. Aquat Toxicol. 2012;120–121:90–8.PubMedCrossRef
45.
Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60:832–8.PubMedCrossRef
46.
van de Wier B, Balk JM, Haenen GR, Giamouridis D, Bakker JA, Bast BC, et al. Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production. FEBS Lett. 2013;587:2461–6.PubMedCrossRef
47.
Besse-Patin A, Estall JL. An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. Int J Cell Biol. 2014;2014:519153.PubMedCentralPubMedCrossRef
Metadata
Title
Exogenous hydrogen sulfide mitigates the fatty liver in obese mice through improving lipid metabolism and antioxidant potential
Authors
Dongdong Wu
Nairui Zheng
Kunqing Qi
Huijun Cheng
Ziqiang Sun
Biao Gao
Youjing Zhang
Wuyan Pang
Chaoshen Huangfu
Shaoping Ji
Mengzhou Xue
Ailing Ji
Yanzhang Li
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Medical Gas Research / Issue 1/2015
Electronic ISSN: 2045-9912
DOI
https://doi.org/10.1186/s13618-014-0022-y

Other articles of this Issue 1/2015

Medical Gas Research 1/2015 Go to the issue

Research

Defining the minimally effective dose and schedule for parenteral hydrogen sulfide: long-term benefits in a rat model of hindlimb ischemia

Study protocol

Convenient methods for ingestion of molecular hydrogen: drinking, injection, and inhalation

Review

Does normobaric hyperoxia increase oxidative stress in acute ischemic stroke? A critical review of the literature

Commentary

Hyperbaric oxygen therapy for post concussion symptoms: issues may affect the results

Research

Pharmacokinetic analysis of the chronic administration of the inert gases Xe and Ar using a physiological based model

Research

The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits